The tech company’s data platform will be implemented into the genomic research department’s workflow.
Stock.adobe.com
Genomics research is growing in importance for the pharma industry with each passing year. One issue that researchers face, however, is the significant amount of data that genomics research generates and requires. Not surprisingly, recent advancements in data technology have caught the eye of many in the life sciences industry.
Texas A&M Health and BurstIQ announced that they have formed a partnership which will leverage BurstIQ’s LifeGraph management platform to improve genomic data governance. The Texas A&M Health PROVENANCE clinicogenomics registry programs will be the primary benefactors of this partnership.
In a press release, Texas A&M’s executive director of clinical, translational, and industry collaborations at the Institute of Biosciences and Technology, Center for Precision and Genomic Medicine Rick Silva, PhD, said, “LifeGraph provides a unique foundation for a modern, data-driven, and scalable approach to collaborative genomics research. By securely linking clinical and non-clinical data in knowledge graphs and allowing patients to make informed decisions about participating in clinical research across time and the patient journey, we can better support patients, institutional data stewards, and enable researchers to derive more value from data. Now we can harness the power of real-world data to transform clinicogenomics research."
In the same press release, BurstIQ CEO Frank Ricotta said, “We are incredibly excited to partner with Texas A&M Health on this revolutionary initiative. LifeGraph's secure handling of sensitive healthcare data opens up new possibilities for transforming research and positively impacting the lives of patients."
BurstIQ has recently partnered with other organizations in healthcare. In July, the company announced that it had formed a partnership with LiteHouse Health, a healthcare staffing platform.
In a press release, Litehouse Health co-founder and chief nursing officer Dr. Ellen Kuhnert said, “At Litehouse Health, we are committed to responding to the needs of our hospital system partners, unlocking local talent, and caring for patients, all with quality as our guide and a commitment to care in the communities we serve. By partnering with BurstIQ to create Litehouse solutions, we're empowering clinicians with the flexibility they deserve while ensuring hospitals have immediate access to the highly qualified talent they need."
In the same press release, Ricotta added, “By utilizing connected nurse profiles, verified credentials, a knowledge graph-powered scheduling ecosystem, and app accelerators, Litehouse Health is maximizing the unique capabilities of the LifeGraph Platform. It's incredibly rewarding to see our advanced data management approach bring such innovative solutions to life."
Also, in March of this year, BurstIQ announced a partnership with Maryville University.3 Once again, the tech company’s data platform was at the center of the partnership.
In a press release, BurstIQ’s chief strategy officer Amber Hartley said, “This partnership reflects Maryville University's unwavering commitment to creating best-in-class administrative operations and student experiences. LifeGraph is uniquely suited to help the university achieve its vision and stay ahead as higher education evolves."
Maryvill University president Mark Lombardi added, “With BurstIQ and the LifeGraph platform, we can support and empower students by managing their educational information in a more holistic way while ensuring their data stays private and secure. LifeGraph provides us with a student-centric data management ecosystem that aligns with Maryville's commitment to providing access and opportunity by empowering success for all students."
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.